BTIG Research resumed coverage on Orthofix with a new price target
$OFIX
Medical/Dental Instruments
Health Care
BTIG Research resumed coverage of Orthofix with a rating of Buy and set a new price target of $27.00
Get the next $OFIX alert in real time by email
Get the next $OFIX alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $OFIX
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $24.00 | Buy | Canaccord Genuity |
| 11/8/2024 | $18.00 → $24.00 | Hold → Buy | Stifel |
| 5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
| 10/20/2023 | $12.00 | Neutral | ROTH MKM |
| 9/12/2023 | Buy → Neutral | BTIG Research | |
| 9/12/2023 | Buy → Hold | Stifel | |
| 7/19/2023 | $27.00 | Buy | BTIG Research |
| 3/4/2022 | $41.00 → $45.00 | Hold → Buy | Stifel |
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319068728/en/TrueLok™ Elevate Transverse Bone Transport (TBT) System TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT procedure has previously been reported,1 TrueLok Elevat
Orthofix Announces Appointment of Vickie Capps to Board of Directors
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa
Orthofix to Participate in the 37th Annual Roth Conference
Monday, March 17, 2025 at 8:00 am Pacific Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the "Events & Presentations" section of the Orthofix investor relations website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investors" section of its website at www.orthofix.com. The Company encourages investors
Canaccord Genuity initiated coverage on Orthofix with a new price target
Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00
Orthofix upgraded by Stifel with a new price target
Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously
Orthofix upgraded by ROTH MKM with a new price target
ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
President & CEO Calafiore Massimo bought $172,801 worth of shares (9,914 units at $17.43), increasing direct ownership by 5% to 222,404 units (SEC Form 4)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
CP&BOO Vitale Lucas sold $71,164 worth of shares (4,287 units at $16.60), decreasing direct ownership by 3% to 135,317 units (SEC Form 4)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
CAO Gillespie Geoffrey C sold $4,914 worth of shares (296 units at $16.60), decreasing direct ownership by 0.69% to 42,521 units (SEC Form 4)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
Director Capps Vickie L was granted 3,093 shares (SEC Form 4)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
Orthofix Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Orthofix Medical Inc. (0000884624) (Filer)
SEC Form S-3ASR filed by Orthofix Medical Inc.
S-3ASR - Orthofix Medical Inc. (0000884624) (Filer)
SEC Form 10-K filed by Orthofix Medical Inc.
10-K - Orthofix Medical Inc. (0000884624) (Filer)
Orthofix Announces Appointment of Vickie Capps to Board of Directors
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa
Patrick Fisher Joins Orthofix as President of Global Orthopedics Business
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Names Stephanie Walsh Chief Human Resources Officer
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results
Company to Host Conference Call on Tuesday, February 25, 2025 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the event passcode 5184023. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Post
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets
Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of 18% compared to third quarter 2023, driven by distribution expansion and further penetration in existi
Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SEC Form SC 13G filed by Orthofix Medical Inc.
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)